Capricor Therapeutics Reports Third Quarter 2026 Financial Results
Capricor Therapeutics reported a net loss of $42.7 million for the third quarter of 2026, missing analyst expectations.
Stocks · News reference
Caprock Mining Corp. Announces Assay Results from Destiny Gold Property Drill Program
Caprock Mining Corp. has completed a three-hole shallow drill program at its Destiny gold property in Quebec, confirming the continuity of mineralization.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Capricor Therapeutics Announces 10% Workforce Reduction
Capricor Therapeutics has implemented a 10% reduction in its workforce as part of a strategic shift to prioritize its lead product candidate.
Capricor Therapeutics' Deramiocel Cardiac Data Wins Outstanding Research Award
Capricor Therapeutics announced that cardiac results from its HOPE-3 Phase 3 trial of Deramiocel for Duchenne muscular dystrophy received the Outstanding Research Award in Pediatric Cardiology at the American Heart Association Scientific Sessions 2026.
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
Capricor Therapeutics announced that its HOPE-3 Phase 3 trial results for Deramiocel in Duchenne muscular dystrophy received the American Heart Association's Outstanding Research Award in Pediatric Cardiology. The cardiac data showed that Deramiocel improved left ventricular ejection fraction by 2.8 percentage points in cardiomyopathy patients (p=0.02) and reduced new heart scarring by 2.9 segments compared to natural history controls (p=0.01). The company's Biologics License Application remains under FDA review with a PDUFA target action date of November 22, 2026.
Clinical Investigators Urge FDA Approval of Deramiocel for Duchenne Muscular Dystrophy
A group of 28 physician-scientists who participated in Capricor's HOPE-3 trial have written to the FDA advocating for the approval of Deramiocel.
Analyst Price Target for Capricor Therapeutics Raised to $27
Analysts have increased the 12-month price target for Capricor Therapeutics, Inc. to $27, reflecting a potential upside based on recent market data.